AU2001258631A1 - Triterpenoid derivatives - Google Patents

Triterpenoid derivatives

Info

Publication number
AU2001258631A1
AU2001258631A1 AU2001258631A AU5863101A AU2001258631A1 AU 2001258631 A1 AU2001258631 A1 AU 2001258631A1 AU 2001258631 A AU2001258631 A AU 2001258631A AU 5863101 A AU5863101 A AU 5863101A AU 2001258631 A1 AU2001258631 A1 AU 2001258631A1
Authority
AU
Australia
Prior art keywords
formula
relates
compound
present
triterpenoid derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258631A
Inventor
Jan Sarek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karlova Univerzita v Praze
Univerzita Palackeho V Olomouci
Original Assignee
Karlova Univerzita v Praze
Univerzita Palackeho V Olomouci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0012532A external-priority patent/GB0012532D0/en
Priority claimed from GB0012825A external-priority patent/GB2362650A/en
Application filed by Karlova Univerzita v Praze, Univerzita Palackeho V Olomouci filed Critical Karlova Univerzita v Praze
Publication of AU2001258631A1 publication Critical patent/AU2001258631A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt, crystal form, complex, hydrate, or hydrolysable ester thereof, in the preparation of a medicament for treating a patient suffering from leukaemia, cancer or other proliferative disorder. A further embodiment relates to the use of a compound of formula (I) in an assay for detecting the phosphorylation state of cellular substrates. The present invention also relates to novel compounds of formula (Ia), and the chemical synthesis thereof.
AU2001258631A 2000-05-23 2001-05-23 Triterpenoid derivatives Abandoned AU2001258631A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0012532 2000-05-23
GB0012532A GB0012532D0 (en) 2000-05-23 2000-05-23 Triterpenoid derivatives
GB0012825A GB2362650A (en) 2000-05-25 2000-05-25 Triterpenoid derivatives
GB0012825 2000-05-25
PCT/GB2001/002341 WO2001090096A2 (en) 2000-05-23 2001-05-23 Triterpenoid derivatives and their use as antiproliferative agents

Publications (1)

Publication Number Publication Date
AU2001258631A1 true AU2001258631A1 (en) 2001-12-03

Family

ID=26244333

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258631A Abandoned AU2001258631A1 (en) 2000-05-23 2001-05-23 Triterpenoid derivatives

Country Status (5)

Country Link
EP (1) EP1289977B1 (en)
AT (1) ATE291573T1 (en)
AU (1) AU2001258631A1 (en)
DE (1) DE60109605T2 (en)
WO (1) WO2001090096A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2008723A3 (en) 2008-11-13 2010-01-13 Univerzita Palackého v Olomouci 2-Deoxyglycosides of triterpenoids, process of their preparation and their use as medicament
CN105534995B (en) * 2016-02-24 2018-05-18 上海交通大学医学院附属仁济医院 Tyrosine kinase inhibitor is preparing the application in treating chronic myelocytic leukemia drug to compound Hu-17 alone or in combination
CN109180775B (en) * 2018-09-05 2021-03-23 常州大学怀德学院 C-28 imine substituted betulin isomer derivative and preparation method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0902685A1 (en) * 1997-01-24 1999-03-24 Marigen S.A. Ultramicro-emulsions of spontaneously dispersible concentrates containing antitumorally, antivirally and antiparasitically active esters of pentacyclic triterpenes

Also Published As

Publication number Publication date
DE60109605T2 (en) 2006-02-02
WO2001090096A2 (en) 2001-11-29
DE60109605D1 (en) 2005-04-28
ATE291573T1 (en) 2005-04-15
WO2001090096A3 (en) 2002-03-07
EP1289977A2 (en) 2003-03-12
EP1289977B1 (en) 2005-03-23

Similar Documents

Publication Publication Date Title
MX2009006742A (en) Novel compounds.
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
MY136174A (en) Phosphonooxy quinazoline derivatives and their pharmaceutical use
HK1051683A1 (en) N-heterocyclic derivatives as nos inhibitors
IL157816A0 (en) Steroids as agonists for fxr
MXPA05013349A (en) 2-aminopyrimidine derivatives as raf kinase inhibitors.
SE9904505D0 (en) Novel compounds
YU23202A (en) Drugs for the treatment of malignant tumors
NO20062019L (en) Β-Glycoprotein Inhibitor, Methods of Preparation thereof, and Pharmaceutical Preparations Containing the Same
UA50719C2 (en) Precursor for therapy of cancer and inflammation
UA89035C2 (en) Hydroxamic acid esters and pharmaceutical use thereof
UA90285C2 (en) Hydantoin derivatives useful as mmp inhibitors
GB0109122D0 (en) Novel compounds
AU2001260445A1 (en) Triterpenoid derivatives
MX2009002998A (en) Pyrazolopyrimidine derivative.
SE1212311T3 (en)
AU2001258631A1 (en) Triterpenoid derivatives
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
AU2002248531A1 (en) Pyrazolopyriadine derivatives
HK1045988A1 (en) Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabeticproperties.
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
WO2003080617A8 (en) Pyrazolopyrimidine derivatives
WO2007001839A3 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
WO2002098399A3 (en) Cancer treatment method and compositions comprising compounds of the ginger family